• 12 February 2020

    BMS positioned to lead in the multiple myeloma market

    Chimeric antigen receptor T-cell (CAR-T) therapies have become standard of care for certain haematological malignancies due to their unprecedented specificity to the patients’ individual immune system. Despite the theoretical advantages,...

  • 12 February 2020

    Failure of DIAN-TU drug trial for Alzheimer’s disease

    Eli Lilly and F. Hoffman-La Roche announced the failure of the clinical trial named DIAN-TU, which was testing two monoclonal antibody (mAb) drugs for Alzheimer’s disease (AD), Roche’s gantenerumab and...

  • 5 February 2020

    Clinical investigations in Coronaviridae infections

    According to the World Health Organization, Coronaviridae or 'coronaviruses' are a large family of viruses that can cause illnesses ranging from the common cold to respiratory symptoms, fever, cough, shortness...

  • 4 February 2020

    Immunotherapies could help to treat acute myeloid leukemia

    Despite immunotherapy combinations revolutionising the treatment of most cancer indications, the acute myeloid leukemia (AML) market has lagged behind. However, with a large number of new agents that target novel...

  • 3 February 2020

    Non-industry-sponsored clinical trials landscape: 2019

    A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution). Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData. When looking at non-industry-sponsored clinical...


Go Top